Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Alamos Gold -- Ignore unavailable to you. Want to Upgrade?

To: Al Collard who wrote (865)	12/22/2001 5:11:52 PM
From: Miner	Respond to of 4470

Hi Al, Hardly a guru, just a wishful stockholder and last place in your winners list. It must have been a tough week. My real account is still under water. The news I was hoping for didn't materialize. There was an optimistic update on their web site though: "With the plant inspection completed, we expect to receive the inspector's written report from the FDA by the end of January. Once we have been officially apprised of the results of this inspection, we will be passing the information along to you. The completion of this important milestone on the road towards FDA approval, will be a signal towards finalization of a PENNSAID® distribution agreement for the US. We are also planning, subject to market conditions, to secure a NASDAQ listing for Dimethaid, to fully capitalize on the potential created by the launch of PENNSAID® into the important US market. The market in the US for NSAIDs is currently estimated to be in excess of $8 billion US, treating an arthritis patient population of over 40 million people. A product with the safety and efficacy of PENNSAID®, when detailed and marketed to US physicians, will offer an exciting new topical solution and a welcome relief for arthritis sufferers. In addition to the US opportunities, 2002 will see the availability of PENNSAID® into other European markets, our long-awaited launch in Canada, and the continuation of research into other products in our planned pipeline. The realization of these events will provide us with the necessary cash reserves to initiate multiple ongoing clinical trials. We have previously discussed the research we are pursuing in onychomycosis (nail fungus), and we are excited also at other potential applications, such as acne. For WF10, to supplement the important research in HIV/AIDS, we anticipate exploring areas such as oncology and other autoimmune diseases. We hope you share our enthusiasm for the opportunities we envision unfolding in 2002." I hope this bodes well in the new year. All the best of the season, and keep up the good work. regards, john

To: Al Collard who wrote (865)	12/28/2001 11:46:51 AM
From: tyc:>	Read Replies (2) \| Respond to of 4470

IMN-T for me please, Al. stockcharts.com[l,a]djclniay[dc][pc20!b50!b100!b200][vc60][iLl14!Lh14,3!La12,26,9]

To: Al Collard who wrote (865)	1/4/2002 4:37:33 PM
From: Al Collard	Read Replies (3) \| Respond to of 4470

Past Winner Alumni List: Week #1 : Buckey TGN-t $24,130.92 Week #2 : Eva AOM-t $24,724.80 Week #3 : tyke -BAS-t $22,467.20 Week #4 : couldawoulda CAE-t $26,254.80 Week #5 : vds4 AC-t $23,269.12 Week #6 : 1st.mate HML-t $28,787.25 Week #7 : KC Jones NTG-t $23,384.10 Week #8 : 1st.mate COG-t $27,290.20 Week #9 : KC Jones CTU.a-t $23,713.20 Week #10: Miner DMX-t $21,361.50 Week #11: Al Collard CDV-t $24,278.20 ...on a weekly $20,000 investment on each of these winning picks an investor would have made $48,410.93 net in the last 11 weeks!!!